Vertex Pharmaceuticals Incorporated ($VRTX) Stock Forecast: Down 18.4% Today

What is Vertex Pharmaceuticals Incorporated?

Vertex Pharmaceuticals (VRTX) is a renowned biotechnology company known for its innovative treatments in various therapeutic areas. The company has been a key player in developing drugs for cystic fibrosis and other serious diseases.

Why is Vertex Pharmaceuticals Incorporated going down?

VRTX stock is down 18.4% on Aug 5, 2025 18:05

• Vertex Pharmaceuticals (VRTX) experienced a strong bearish movement today.
• The bearish trend could be attributed to analysts cutting their forecasts for the company after the Q2 results, despite reporting better-than-expected earnings. This adjustment may have led to a loss of investor confidence.
• Additionally, the disappointing results of the VX-993 trial might have contributed to the negative sentiment surrounding the stock, as investors may have been expecting more positive outcomes.
• Overall, the combination of lowered forecasts and unsatisfactory trial results likely led to the bearish movement in Vertex Pharmaceuticals' stock today.

VRTX Price Chart

VRTX Technical Analysis

VRTX News

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results - Vertex Pharmaceuticals ( NASDAQ:VRTX )

Vertex Pharmaceuticals Inc VRTX reported better-than-expected earnings for the second quarter after the market close on Monday. The company's revenue came in at $2.97 billion versus estimates of $2.90 billion. Adjusted EPS came in at $4.52, versus estimates of $4.29.

https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46867232/these-analysts-cut-their-forecasts-on-vertex-pharmaceuticals-after-q2-results

Inspire Medical Systems, Ichor Holdings, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Inspire Medical Systems ( NYSE:INSP ) , Ichor Holdings ( NASDAQ:ICHR )

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.1% on Tuesday. Shares of Inspire Medical Systems, Inc. INSP fell sharply in pre-market trading after the company reported second-quarter results and cut its FY25 guidance below estimates.

https://www.benzinga.com/trading-ideas/movers/25/08/46854602/inspire-medical-systems-ichor-holdings-vertex-pharmaceuticals-and-other-big-stocks-moving-lo

Vertex Pharmaceuticals Stock Falls on Q2 Earnings, VX-993 Trial Results - Palantir Technologies ( NASDAQ:PLTR )

Vertex beats analyst estimates on the top and bottom lines in the second quarter. Vertex announces treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint in a Phase 2 study. The market's back, and these 3 income stocks are thriving. See them here→

https://www.benzinga.com/markets/earnings/25/08/46841570/vertex-pharmaceuticals-stock-dives-after-q2-earnings-phase-2-results-for-vx-993

Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Vertex Pharmaceuticals ( NASDAQ:VRTX )

Vertex Pharmaceuticals Incorporated VRTX will release earnings results for the second quarter, after the closing bell on Monday, Aug. 4. Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.25 per share, versus a year-ago loss of $12.83 per share.

https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46835352/vertex-pharmaceuticals-likely-to-report-q2-profit-these-most-accurate-analysts

Here's How Much $1000 Invested In Vertex Pharmaceuticals 15 Years Ago Would Be Worth Today - Vertex Pharmaceuticals ( NASDAQ:VRTX )

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 6.26% on an annualized basis producing an average annual return of 18.33%. Currently, Vertex Pharmaceuticals has a market capitalization of $117.41 billion.

https://www.benzinga.com/insights/news/25/08/46801957/heres-how-much-1000-invested-in-vertex-pharmaceuticals-15-years-ago-would-be-worth-today

Trending Today

Monero ($XMR) Crypto Forecast: Up 6.3% Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.3% Today

Vertex Pharmaceuticals Incorporated Price History

11.03.2025 - VRTX Stock was up 5.0%

• Vertex Pharmaceuticals (VRTX) stock had a strong bullish movement today, possibly driven by the news of securing approval for the expanded use of its CF drug Kaftrio in Europe.
• The expanded use of Kaftrio to treat a larger population in the EU with rare mutations of cystic fibrosis could have positively impacted investor sentiment and contributed to the stock's upward momentum.
• The positive news of regulatory approval for Vertex's drug in a new market could have instilled confidence in investors regarding the company's growth potential and future revenue streams, leading to the bullish movement in the stock price today.

19.11.2024 - VRTX Stock was down 17.1%

• The investigation for potential securities fraud could have caused uncertainty and negative sentiment among investors, leading to the bearish movement in VRTX stock.
• The bullish stance taken by wealthy investors might not have been enough to offset the impact of the securities fraud investigation on the stock.
• Despite outperforming the market over the past 20 years, the current investigation news seems to have overshadowed any positive long-term performance, contributing to the bearish movement in VRTX today.

19.11.2024 - VRTX Stock was down 10.8%

• Vertex Pharmaceuticals reported less-than-promising Phase 2 results for suzetrigine in treating painful lumbosacral radiculopathy, raising doubts about the drug's effectiveness and market potential.
• Concerns arose among investors following an investigation into securities fraud by Block & Leviton, leading to a decrease in confidence and a sell-off of VRTX shares.
• Despite some positive interest from affluent investors, negative news and legal issues may have dominated sentiment surrounding Vertex Pharmaceuticals.
• The stock's weaker performance compared to the market overall and its performance in relation to peers like Bristol Myers Squibb likely contributed to the downward trend.

31.00.2025 - VRTX Stock was up 5.6%

• VRTX saw a decrease of -0.72% amidst the overall bullish market trend.
• Investor sentiment towards VRTX might have been impacted by a recent downgrade from an Everest Group analyst.
• The altered outlook could have prompted caution among investors, resulting in a slight retreat in the stock's value.
• When trading VRTX, it is important for traders to weigh both analyst evaluations and market patterns.

13.00.2025 - VRTX Stock was down 1.9%

• Vertex Pharmaceuticals (VRTX) encountered a bearish trend attributed to a Death Cross, signaling a downturn as the stock dropped beneath crucial moving averages.
• Clinical trial setbacks and technical sell signals exerted downward pressure on VRTX, resulting in a 15% decrease over the last half-year.
• Despite recent negativity, Vertex Pharmaceuticals has historically surpassed the market, boasting a 20.1% average annual return over 20 years.
• Investor comparisons of VRTX against peers in the Medical Biomedical and Genetics sector, such as Incyte (INCY), potentially influenced the bearish outlook on Vertex Pharmaceuticals today.

05.07.2025 - VRTX Stock was down 18.4%

• Vertex Pharmaceuticals (VRTX) experienced a strong bearish movement today.
• The bearish trend could be attributed to analysts cutting their forecasts for the company after the Q2 results, despite reporting better-than-expected earnings. This adjustment may have led to a loss of investor confidence.
• Additionally, the disappointing results of the VX-993 trial might have contributed to the negative sentiment surrounding the stock, as investors may have been expecting more positive outcomes.
• Overall, the combination of lowered forecasts and unsatisfactory trial results likely led to the bearish movement in Vertex Pharmaceuticals' stock today.

31.00.2025 - VRTX Stock was up 6.9%

• VRTX stock experienced a strong bullish movement.
• Vertex Pharmaceuticals secured FDA approval for a non-opioid pain treatment and reached a reimbursement agreement with NHS England for its gene therapy, driving positive sentiment.
• The market reacted positively to these advancements in pain management and expanded access to treatments for sickle cell disease, propelling VRTX stock higher.

05.07.2025 - VRTX Stock was down 13.7%

• There was a notable downward movement in the stock today.
• Recent reports on Q2 earnings and VX-993 trial outcomes fell short of projections, contributing to a decrease in the stock's value.
• Despite a generally positive market environment, with Dow futures seeing a slight increase of about 0.1%, Vertex Pharmaceuticals experienced a substantial decline following disappointing trial results.
• Analysts have been closely monitoring the company's stock performance, noting its history of outperforming the market but encountering challenges in the current quarter.

14.04.2025 - VRTX Stock was down 5.3%

• Despite Vertex Pharmaceuticals' strong performance over the past 15 years, the stock faced a bearish movement today.
• Speculation that Vertex Pharmaceuticals will bounce suggests that there may be underlying factors contributing to the temporary decline.
• The market may be reacting to short-term fluctuations or profit-taking by investors, leading to the bearish movement in VRTX today.
• Investors should monitor the situation closely to determine if this is a temporary dip or the beginning of a more sustained trend.

08.06.2025 - VRTX Stock was up 2.3%

• Vertex Pharmaceuticals (VRTX) saw a strong bullish movement, closing at $452.16 with a +1.56% change.
• The bullish movement in VRTX could be attributed to positive developments in its pipeline or potential regulatory approvals.
• Despite the overall market dip, investors showed confidence in Vertex Pharmaceuticals, possibly due to promising clinical trial results or optimistic revenue forecasts.
• The resilience of VRTX in a slightly bearish market indicates strong investor sentiment and belief in the company's growth prospects.

06.04.2025 - VRTX Stock was down 10.9%

• Experienced a strong bearish movement today.
• Fell after missing analyst estimates on both earnings and revenue for the first quarter.
• Despite raising the low end of its full-year 2025 revenue guidance, the market reacted negatively to the missed expectations.
• Analyst downgrades and concerns about the company's recent performance may have contributed to the bearish trend in the stock price.

11.02.2025 - VRTX Stock was down 2.7%

• The bearish movement in VRTX stock today might be due to the pricing placement of their newly approved pain treatment, Journavx, on UnitedHealth's Optum Rx formularies.
• Concerns may arise over the $15.50 cost per 50 mg tablet of Journavx, which surpasses that of opioids, potentially affecting its market acceptance and profitability.
• Despite Vertex's robust Q4 sales figures, market response to Journavx's pricing strategy could have overshadowed positive financial outcomes, contributing to the downtrend in the stock price today.